Lineage Cell Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.6 | $9.5 | $8.9 | $14.7 | $4.3 |
| Operating income | -$36.6 | -$21.5 | -$24.7 | -$22.5 | -$49.2 |
| Net income | -$63.5 | -$18.6 | -$21.5 | -$26.3 | -$43.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$19.4 | -$23.7 | -$29.2 | $0.6 | -$23.9 |
Shares outstanding 252.9M · Free float 46.2%
Annual filing data through FY ended December 31, 2025; float as of September 7, 2026.